FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3173646711> ?p ?o ?g. }

• W3173646711 endingPage "88" @default.
• W3173646711 startingPage "82" @default.
• W3173646711 abstract "After surgical resection of papilloma, adjuvant therapy may be recommended for the control of recurrent respiratory papillomatosis (RRP). As the efficacy of adjuvant therapy remains unproven, the aim of this study was to compare the efficacy of cidofovir versus bevacizumab used as adjuvant therapies for the control of RRP. This randomized, double-blind, placebo-controlled pilot study was performed in a national respiratory disease referral centre. Patients with RRP were recruited prospectively and were divided into juvenile or adult RRP. Participants were randomly assigned to receive adjuvant therapy with cidofovir, bevacizumab or placebo. The study drug or placebo was administered after direct microlaryngoscopy with papilloma resection using cold instruments. The Derkay severity score and the Voice Handicap Index (VHI) were assessed at 3–6-week intervals, for a total of 3 visits. Follow-up included VHI and Derkay score assessments at 2-month intervals over the course of one year. Annual rates before and after surgical treatment were compared. Five children and 11 adults were enrolled in the study. After one year, the group treated with cidofovir had a significant decrease in Derkay score ( p = .027). No difference between treatment arms was observed in the annual surgery rate. There was a significant decrease in the VHI score in all treatment groups ( p < .001), and no significant difference was observed between groups ( p = .32). While we observed a significant decrease in RRP severity with intralesional cidofovir, we were unable to provide proof of efficacy of intralesional bevacizumab. Clinicaltrials.gov Identifier: NCT02555800 . Tras la extirpación quirúrgica de los papilomas, puede recomendarse terapia adyuvante para el control de la papilomatosis respiratoria recurrente (PRR). Como la eficacia de la terapia adyuvante no está demostrada, el objetivo de este estudio fue comparar la eficacia de cidofovir frente a bevacizumab, utilizados como terapias adyuvantes para el control de PRR. Estudio piloto aleatorizado, doble ciego y controlado por placebo, realizado en un centro nacional de referencia de enfermedades respiratorias. Se reclutó prospectivamente a los pacientes con PRR, y se dividieron en 2 grupos: PRR de jóvenes y PRR de adultos. A los participantes se les asignó aleatoriamente la administración de terapia adyuvante de cidofovir, bevacizumab o placebo. La administración de los fármacos de estudio o placebo se realizó tras practicar microlaringoscopia directa con extirpación de papilomas, utilizando instrumental frío. Se llevaron a cabo evaluaciones utilizando la puntuación de gravedad de Derkay y la escala VHI (Voice Handicap Index) a intervalos de 3 a 6 semanas, con un total de 3 visitas. El seguimiento incluyó evaluación de las escalas VHI y Derkay a intervalos de 2 meses, durante el curso de un año. Se compararon las tasas anuales pre- y postratamiento quirúrgico. El estudio incluyó 5 niños y 11 adultos. Transcurrido un año, el grupo tratado con cidofovir reflejó una reducción significativa en la escala Derkay (p = 0,027). No se observó diferencia alguna entre las ramas terapéuticas en la tasa quirúrgica anual. Se vio una reducción significativa en la puntuación VHI en todos los grupos terapéuticos (p < 0,001), y no se observó diferencia significativa entre los grupos (p = 0,32). A pesar de verse una reducción significativa de la gravedad de PRR con la administración de cidofovir intralesional, no pudimos probar la eficacia de bevacizumab intralesional." @default.
• W3173646711 created "2021-07-05" @default.
• W3173646711 creator A5002993537 @default.
• W3173646711 creator A5012673151 @default.
• W3173646711 creator A5019470243 @default.
• W3173646711 creator A5028406581 @default.
• W3173646711 creator A5060189813 @default.
• W3173646711 creator A5064465687 @default.
• W3173646711 creator A5071963722 @default.
• W3173646711 date "2022-03-01" @default.
• W3173646711 modified "2023-09-30" @default.
• W3173646711 title "Efficacy of cidofovir versus bevacizumab in recurrent respiratory papillomatosis: A randomized, double-blind, placebo-controlled pilot study" @default.
• W3173646711 cites W1561349740 @default.
• W3173646711 cites W1863180087 @default.
• W3173646711 cites W1988505863 @default.
• W3173646711 cites W1997082231 @default.
• W3173646711 cites W2006013614 @default.
• W3173646711 cites W2007779260 @default.
• W3173646711 cites W2020667364 @default.
• W3173646711 cites W2052465373 @default.
• W3173646711 cites W2069902485 @default.
• W3173646711 cites W2072326665 @default.
• W3173646711 cites W2084783355 @default.
• W3173646711 cites W2093759117 @default.
• W3173646711 cites W2096411388 @default.
• W3173646711 cites W2103128963 @default.
• W3173646711 cites W2106755830 @default.
• W3173646711 cites W2130596081 @default.
• W3173646711 cites W2142126331 @default.
• W3173646711 cites W2143104495 @default.
• W3173646711 cites W2150147928 @default.
• W3173646711 cites W2168611355 @default.
• W3173646711 cites W2319966627 @default.
• W3173646711 cites W2401604009 @default.
• W3173646711 cites W2406671513 @default.
• W3173646711 cites W2619263639 @default.
• W3173646711 cites W2782925962 @default.
• W3173646711 cites W2811181828 @default.
• W3173646711 cites W2884876202 @default.
• W3173646711 cites W2898275089 @default.
• W3173646711 cites W2916983081 @default.
• W3173646711 cites W2973515423 @default.
• W3173646711 doi "https://doi.org/10.1016/j.otorri.2020.12.001" @default.
• W3173646711 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34154795" @default.
• W3173646711 hasPublicationYear "2022" @default.
• W3173646711 type Work @default.
• W3173646711 sameAs 3173646711 @default.
• W3173646711 citedByCount "3" @default.
• W3173646711 countsByYear W31736467112023 @default.
• W3173646711 crossrefType "journal-article" @default.
• W3173646711 hasAuthorship W3173646711A5002993537 @default.
• W3173646711 hasAuthorship W3173646711A5012673151 @default.
• W3173646711 hasAuthorship W3173646711A5019470243 @default.
• W3173646711 hasAuthorship W3173646711A5028406581 @default.
• W3173646711 hasAuthorship W3173646711A5060189813 @default.
• W3173646711 hasAuthorship W3173646711A5064465687 @default.
• W3173646711 hasAuthorship W3173646711A5071963722 @default.
• W3173646711 hasConcept C126322002 @default.
• W3173646711 hasConcept C142724271 @default.
• W3173646711 hasConcept C143998085 @default.
• W3173646711 hasConcept C159047783 @default.
• W3173646711 hasConcept C16005928 @default.
• W3173646711 hasConcept C168563851 @default.
• W3173646711 hasConcept C204787440 @default.
• W3173646711 hasConcept C2522874641 @default.
• W3173646711 hasConcept C27081682 @default.
• W3173646711 hasConcept C2776694085 @default.
• W3173646711 hasConcept C2776824251 @default.
• W3173646711 hasConcept C2777063820 @default.
• W3173646711 hasConcept C2777802072 @default.
• W3173646711 hasConcept C2910019179 @default.
• W3173646711 hasConcept C2991744798 @default.
• W3173646711 hasConcept C2994532551 @default.
• W3173646711 hasConcept C71924100 @default.
• W3173646711 hasConceptScore W3173646711C126322002 @default.
• W3173646711 hasConceptScore W3173646711C142724271 @default.
• W3173646711 hasConceptScore W3173646711C143998085 @default.
• W3173646711 hasConceptScore W3173646711C159047783 @default.
• W3173646711 hasConceptScore W3173646711C16005928 @default.
• W3173646711 hasConceptScore W3173646711C168563851 @default.
• W3173646711 hasConceptScore W3173646711C204787440 @default.
• W3173646711 hasConceptScore W3173646711C2522874641 @default.
• W3173646711 hasConceptScore W3173646711C27081682 @default.
• W3173646711 hasConceptScore W3173646711C2776694085 @default.
• W3173646711 hasConceptScore W3173646711C2776824251 @default.
• W3173646711 hasConceptScore W3173646711C2777063820 @default.
• W3173646711 hasConceptScore W3173646711C2777802072 @default.
• W3173646711 hasConceptScore W3173646711C2910019179 @default.
• W3173646711 hasConceptScore W3173646711C2991744798 @default.
• W3173646711 hasConceptScore W3173646711C2994532551 @default.
• W3173646711 hasConceptScore W3173646711C71924100 @default.
• W3173646711 hasIssue "2" @default.
• W3173646711 hasLocation W31736467111 @default.
• W3173646711 hasOpenAccess W3173646711 @default.
• W3173646711 hasPrimaryLocation W31736467111 @default.
• W3173646711 hasRelatedWork W2006182541 @default.
• W3173646711 hasRelatedWork W2054338392 @default.
• W3173646711 hasRelatedWork W2089551862 @default.

• next